GERPACYST- The Trial Protocol Of The Prospective, Multicenter,

1

2

Interdisciplinary German Pancreas Club Cyst Registry

3 4 Kim Christin Honselmann¹, Jonathan Marschner¹, Anna Staufenbiel¹, Julia Bertram ¹, Steffen 5 Deichmann¹, Carsten Engelke ², Martha Kirstein ², Jens Marguardt ², Marko Damm³, Fanny 6 Borowitzka ⁴, Veit Phillip ⁵, Ilaria Pergolini⁶, Felix Harder⁷, Rickmer Braren⁷, Timo Gemoll¹, 7 Susanne Roth¹¹, Sebastian Krug¹⁵, Christoph W. Michalski ¹¹, Robert Jaster⁴, Tobias Keck ¹, 8 Ulrich Friedrich Wellner¹, and the GERPACYST Study Group^{8-10,12-14} 9 10 ¹ Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, Germany, 11 Ratzeburger Allee 160, 23538 Lübeck, Germany 12 ² Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Campus Luebeck 13 ³ Department of Internal Medicine I, University Medical Center Halle, Germany 14 ⁴ Department of Internal Medicine, University Medical Center Rostock, Germany 15 ⁵ TUM School of Medicine and Health, Department of Clinical Medicine – Clinical Department for 16 Internal Medicine II, University Medical Center, Technical University of Munich, Munich, Germany 17 ⁶ Department of Surgery, University Medical Center, Technical University of Munich, Munich, Germany 18 ⁷ Department of Radiology, University Medical Center, Technical University of Munich, Munich, 19 Germany 20 ⁸ Department of Surgery, Hospital Neustadt, Neustadt/Holstein, Germany 21 ⁹ Section of Interdisciplinary Pancreatology, Department of Internal Medicine I, Ulm University 22 Hospital, Germany 23 ¹⁰ Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, 89081 Ulm, Germany 24 ¹¹ Department of Gastrointestinal & Infectious Diseases and Surgery, University Medical Center 25 Heidelberg, Germany 26 ¹² Department of Surgery, University Hospital Ulm, Germany 27 ¹³ Department of Internal Medicine I, University Medical Center Regensburg, Regensburg, Germany 28 ¹⁴ Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical 29 COTE TRIPETING CONCENTED ACTION AND ACTION ACTION AND ACTION ACTION ACTION AND ACTION AC 30 ¹⁵ Department of Gastroenterology, University Medical Center Heidelberg, Germany

31 Corresponding Author and Reprints: 32 Prof. Tobias Keck, Department Chair 33 Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, 34 Ratzeburgerallee 160, 23538 Luebeck 35 Phone: 0451 500 40120, E-mail: Tobias.Keck@uksh.de 36 37 Parts of the study are currently funded by The Federal Ministry of Education and Research 38 (BMBF) (Funding number: 01KD2412A) and was supported by the Clinician-scientist school 39 Luebeck (project number 413535489) to KCH. 40 41 The study protocol has been presented at the annual meeting of the Digestive Disease Week 42 2024 and the German Society of Visceral Medicine 2023. 43 44 There are no conflicts to declare. Data is available from the first author KCH. 45 Revision chronology: Dec. 1st, 2023 Original 46 47 December 7th, 2023, 1st. Revision 48 December 12th, 2023 2nd Revision 49 January 11th, 2024 3rd Revision 50 August 13th, 2024 4th Revision 51

52 **Abstract**

Background

53

61 62

71

72

76 77

81 82

86 87

89

- 54 Cystic lesions of the pancreas have continued to present a clinical challenge for the past
- 55 decades now. The increasing rate of detection, the lack of high-quality data on the natural
- 56 biology of pancreatic cysts and the resulting difficulty to predict malignant transformation in
- different types of pancreatic cysts make patients with these diseases hard to manage. 57
- 58 The German Pancreas Club Cyst Registry (GERPACYST) (DRKS00025927) establishes a
- 59 platform to discover the natural entity specific biology of pancreatic cysts, in a multicenter
- 60 manner that should allow to assess risk models for malignancy.

Method

- 63 This manuscript is written according to the SPIRIT guidelines. Ethical approval was obtained
- 64 from the University of Luebeck (2024-265 1). In GERPACYST patients aged ≥18 years with a
- pancreatic cyst under surveillance or scheduled for surgery should be enrolled. Participating 65
- 66 centers will complete an electronic Case Report Form (eCRF) via REDCap which is designed
- 67 as a longitudinal study minimizing the input of repeated measures. Changes in patient baseline
- 68 data, cyst characteristics, both endoscopic and imaging data will be entered typically every 6-
- 69 12 months during patient follow-up. Biobanking will be performed, when available. Duration of
- 70 observation per patient is up to a maximum of 20 years or until end of follow-up or death.

Discussion

- 73 GERPACYST will provide a valuable platform for clinical outcomes research. Fundamental
- 74 factors affecting the development of pancreatic cysts over time will be identified. New research
- 75 questions might be answered during the study period.

Trial registration

- 78 The study was prospectively registered at the German Clinical Trial Register (DRKS) under
- 79 DRKS00025927 on September, 14th, 2021 before inclusion of the first patient. The Universal
- 80 Trial Number (UTN) is U1111-1302-9822.

Trial sponsor

- 83 The study is sponsored by the German Pancreas Club (DPC) e.V. The sponsor has no role in
- 84 study design, collection, management, interpretation or writing of the report. It is a mere
- 85 supportive sponsoring.

Keywords:

88 Pancreatic cyst, Clinical registry, GerPaCyst, IPMN, SCN, SPPT, MCN

GERPACYST Study Group

90

- 91 Louisa Bolm ¹, Rüdiger Braun ¹, Rene Wilke ³, Fanny Borowitzka ⁴, Sebastian Rasch ⁵, Ihsan
- Ekin Demir ⁶, Lukas Perkhofer ^{9,10}, Alexander Kleger ^{9,10}, Felix Huettner ^{12,}, Philip Hildebrandt ⁸, ⁷, 92
- 93 Sophie Schlosser-Hupf ¹³, Martina Müller¹³, Christoph Ammer-Hermenau ¹⁴, Albrecht Neesse ¹

Background

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

Cystic lesions of the pancreas can either be neoplastic or non-neoplastic. Neoplastic cystic lesions include intraductal mucinous papillary neoplasms (IPMN), mucinous cystic neoplasms (MCN), serous cystic neoplasms (SCN) and solid pseudopapillary tumors (SPPT) and make up 90% of all neoplastic cystic tumors of the pancreas (1). Depending on the entity, pancreatic cysts bear malignant potential that is associated with outcomes comparable to pancreatic cancer (2). However, diagnostic accuracy remains limited (3). The accuracy of cross-sectional imaging varies between 39.5% and 46%. Pancreatic cysts occur in up to 45% in the German population (4). The incidence is roughly 13% in Germany and the management of pancreatic cysts has therefore become a highly relevant clinical issue. Recent improvements in high-resolution imaging that make their detection more frequent stands in contrast to treatment algorithms that remain highly controversial in the absence of high- quality controlled studies. Between 2012 and 2018 international guidelines for the treatment of pancreas cysts were published (5-8). All these quidelines make different recommendations on surveillance of small cysts after five years (9). However, most of these recommendations are under the bias of retrospective surgical series and observational studies (10, 11). Thus, they probably overestimate the potential for malignancy. Analyses that go beyond five or even ten years hardly exist, which makes it difficult to predict the biology of these entities (12). Furthermore, the knowledge about the longterm risk of IPMN developing in pancreatic cancer is contradictory. Crippa et al. reported an overall risk of 3.7% of IPMNs to develop into pancreatic cancer (13). Choi et al. reported that a low risk IPMN (lesion without main pancreatic duct involvement or mural nodes) has a 7,8% chance after 10 years to progress into pancreatic cancer and a high risk IPMN (mural nodes and dilatated main pancreatic duct) has 25% chance after 10 years to progress into pancreatic cancer (14). In essence, the natural biologic history of most of the pancreatic cysts we treat today, is unclear. Therefore, we aim to establish the GERPACYST registry, a prospective, 20-year

123

124

125

126

127

spanning, interdisciplinary, multicenter registry to structurally study the natural biology of different pancreatic cysts over time in order to build multidimensional models to calculate the individual's risk for the development of malignancy.

Methods

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

152

153

155

Aims and scope of the registry study

The registry was developed to provide a framework for studying the natural history of pancreatic cystic lesions. The study idea was initially established at the German Pancreas Club meeting 2020 and is endorsed and sponsored by the German Pancreas Club (DPC). With regard to the above-mentioned aim, the following aspects were especially considered by the founding team (KCH, JM, CWM, SK, RJ, PV, MD, TK, PV, SR and UFW). Relevant outcomes and patient variables were chosen by the founding team. Definitions of the International Study Group of Pancreatic Surgery (ISGPS), the TNM classification system, the German S3 guideline for the treatment of pancreatic cancer and the Fukuoka guidelines were

utilized. The updated Kyoto guidelines were added August 13th, 2024.

Study design

The GERPACYST Study is a prospective, multicenter, interdisciplinary, longitudinal registry study. A formal protocol detailing aims and regulations for data safety and publication has been uploaded to https://drks.de/search/en/trial/DRKS00025927 and can be accessed publicly. This manuscript also provides a concise form to fulfill standards for documentation of registries and follows the Standard protocol items: recommendations for clinical trials (SPIRIT) guidelines (15).

Registry organization

- 149 The GERPACYST-registry is headed by the Steering Committee including KCH, MD, RJ, SK,
- 150 CM and UFW. The registry is physically located at the University of Luebeck, Germany.
- 151 Maintenance is secured by the IT-Service Center Luebeck.

Participants, eligibility criteria and outcomes

154 Patients presenting in the clinic of the participating centers including academic and academic-

affiliated hospitals currently all in Germany with a presumed or confirmed pancreatic cyst

perpetuity.

It is made available under a CC-BY 4.0 International license .

(IPMN, MCN, SPPT, or SCN) and at minimum 18 years old will be evaluated to participate in

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

the study. Inclusion criteria: -presumed pancreatic cyst of the following entities (IPMN, MCN, SPPT, SCN) - at least 18 years old **Exclusion criteria:** Confirmed pseudocyst or diagnosis other than IPMN, MCN, SPPT, SCN Less than 18 years old Suitable patients will be informed about the research project by the treating physician. The written informed consent will be obtained by each patient. The treatment interventions will not be altered by the study. If the patient gives consent to participate in GERPACYST, data entry will occur at the time of treatment initiation (surgery or start of non-surgical surveillance) and every 6-12 months after treatment initiation for a period not to exceed 20 years. Participating centers complete an electronic Case Report Form (eCRF). Study data is collected and managed using REDCap electronic data capture tools hosted at the University of Luebeck, Germany (16, 17) (Variables see Supplementary Table 1). Changes in patient characteristics are entered during patient follow-up. In addition, patient biobank samples (blood, cyst fluid, urine, tissue) will be stored upon availability. The primary outcome of this trial is the development of high-grade dysplasia/invasive cancer during follow-up or the absence of it. The secondary outcomes are death, quality of life measured by EQ-5D-5L questionnaire, end-of-follow up and perioperative characteristics if applicable such as complications, length of hospital stay, clavien-dindo classification. **Initiation algorithm** The study is still welcoming new participating centers from all over the world. Interested centers can contact: kim.honselmann@uksh.de or redcap.lachi@uni-luebeck.de. Once the study

protocol has been reviewed by the ethics committee of the new center, and the contract has been approved by both legal departments, the participating physicians will receive proper training for patient inclusion in the REDCAP based database.

Participant timelines and follow-up schedules

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

Only after the patient has given written informed consent may the treating physician register the patient in the database. After patient registration, mandatory baseline data on premedical history, data on the disease, imaging and diagnostic modalities, treatment, and treatment outcome (e.g., post-op complications) are documented. In addition, the date of treatment initiation, patient number, and basic patient-specific information are documented (e.g., gender or month and year of birth). The study's non-interventional design does not regulate modalities or intervals between examinations and thus does not intervene in routine clinical practice. Patients will be followed when presenting to the participating institutions or by telephone interview every 6-12 months. A detailed patient schedule is shown in Figure 1.

Patient rights and data safety

Written informed consent for participation in the registry is obtained prior to inclusion at every center from all patients. Patient data are entered and stored in pseudonymized form. Institutional review boards have been obtained from every participating center. A data safety manual can be obtained from the senior author (KCH). The GERPACYST platform was initiated and enabled for data collection in pancreatic cysts in 2021 (Ethics Committee of the University of Lübeck Az. 20-225 and 2024-265 1).

Assessment of data

After browser-based data entry, the data are automatically checked for completeness and internal plausibility by software-based internal rules. Missing or implausible items create warning messages. The data is usually entered after seeing the patient in the outpatient clinic

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

of the respective institution. Missing data will be handled according to the intended analysis. There is currently no external monitoring for the GERPACYST Registry. **Database structure** GERPACYST is based on a web-based REDCAP data entry system for the systematic collection of patient data, which was developed by Vanderbilt University (16). Data entry is paperless and performed directly on-site at the respective medical facility (clinic/practice) via an Internet browser. The REDCAP implementation meets all requirements of Good Clinical Practice (ICH-GCP) as well as European data safety regulations. Corresponding certificates for data security are available. The system is operated on a server of the computer center of the University of Lübeck and is thus subject to strict access control. Data is collected in pseudonymized form. Pseudonymization keys are kept separately from the database at the participating institutions. Duration of observation per patient is up to a maximum of 20 years or until the occurrence of an event defined as end of follow-up or death. The study start was the fourth quarter of 2021 and is still ongoing. Centers are still initialized at the moment. Entered variables include: baseline characteristics such as data on comorbidities like arterial hypertension, diabetes mellitus, chronic obstructive lung disease, medical history of cancer, family history and past medical history. Also, data on perioperative characteristics, if applicable, will be collected. Imaging modalities on the most prominent cysts will be collected at each follow-up. We will perform a quality-of-life questionnaire (EQ-5D-5L) at enrollment and at end of follow-up or surgery (18). Cyst fluid analysis/molecular characteristics will be collected, if available (Supplementary Table 1). **Statistics** The data required for the respective research question are compiled into an anonymized project-specific evaluation data set with special consideration of the resulting re-identification

perpetuity.

It is made available under a CC-BY 4.0 International license.

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

risk, if any, and made available for the research project. The GERPACYST study group decides on the provision of the evaluation data sets for scientific evaluation. For the development of risk models, we aim to utilize neuronal networks with elastic-net regression using R. ROC-Curves will be built for candidate risk variables. According to our and experience of others, sample size should be ten to 20 times higher than the number of trainable parameters. As of now, we are planning to include 157 variables plus imaging and biomarker profiles (about 40 different parameters). Our sample size should therefore be at least 4000 patients (200x20). In order to achieve adequate participant enrolment, this study was set up as a multicenter study internationally. Descriptive data will be evaluated with R or SPSS according to the data characteristics. Nominal data will be evaluated with frequencies and percentages and differences with Chi-square test or the Kaplan-Meyer methods if pertaining to survival. Continuous data will be evaluated by median and interguartile range, differences between two groups will be calculated by Mann-Whitney U Test. Kaplan-Meyer approximation will be used for survival analyses. P-value will be set at p<0.05. The further exact analyses will be defined in a Statistical Analysis Plan (SAP) prior to the corresponding evaluation. However, to ensure appropriate analyses, the nature of the data must be considered. For this reason, descriptive analyses will be conducted, from which new hypotheses and questions will arise. In particular, potential systematic biases must be identified and accounted for in the analyses. Other important decisions include defining subgroups of interest (e.g., patient groups that are usually excluded from RCTs) or pooling similar therapies (e.g., when there are only a few patients in individual therapies) and dealing with missing values in registry data. Some of the questions result in periodic evaluations. Other questions arise due to the ongoing, observational process only in the course of the study, which then result in supplementary SAPs. Answering questions that arise only in the course of the study is one of the great advantages (and difficulties) of registry studies (19). Only the ITSC of the University of Lübeck and the leaders of the GERPACYST study group or persons appointed by the study group, such as staff of the Chir-NET office of the University Hospital Schleswig-Holstein, have access to the complete data set.

The GerPaCyst registry has been established to be used together with the StuDoQIPancreas Registry, if necessary and for facilitating data use and transfer within Germany, but also internationally. Many items have been adapted from the StuDoQIPancreas registry, accordingly (20).

Declaration of interest

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

None of the authors declare financial or competing interest for the overall trial and each study site.

Dissemination policy

Trial results will be communicated with all participating centers on a regular basis including half-yearly meeting sessions at the German Pancreas Club and the German Visceral Medicine meetings (AG Pankreas DGVS). In addition, 4-monthly group meetings will be held virtually in order to communicate possible protocol changes or interim-results. Publication will be decided upon by the steering committee and author inclusion will be based on patient inclusion: up to 10 patients per year: 1 author from each center, 10 to 20 patients per year: 2 authors per center, etc. Requests for data analysis of the whole cohort can be send to the steering committee for evaluation. The full protocol has been uploaded to the german clinical trial registry (www.drks.de). Participant-level dataset and statistical codes can be obtained from KCH.

Biological Specimens

Blood samples or cyst (fluid) biopsies or surgical specimens will be collected at the participating centers, if available and will possibly be used for genetic and molecular analysis in ancillary studies in the future.

Appendices

Informed consent (Currently in German).

Discussion

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

More than twenty years after the first introduction of intraductal papillary mucinous neoplasms (IPMN) by the World Health Organization (WHO), we still struggle to treat not only IPMNs, but most pancreatic cysts. The increasing frequency of detection caused by the rising number of radiology imaging exams will make this an even more pressing issue in the not so far future. A large surgical series of 577 branch-duct IPMNs (BD-IPMN) found that at a median follow-up of nearly seven years, almost 50% of BD-IPMNs progressed over time with 34% of patients having either worrisome features or high-risk stigmata at the end of follow up (10). In contrast, a radiologic group found no development of malignancy in a group of 49 patients with BD-IPMNs less than 2 cm in diameter (21). Similarly, in an Asian study only 9% of 722 patients developed malignancy over a five-year follow up-period (22). A recent large study from Verona showed that the risk of developing malignancy in presumed BD-IPMN, that are stable over five years and less than 30mm in size was comparable to that of the general population in the same age group. They even proposed to discontinue surveillance in patients older than 75 years (23). However, the median follow-up was less than five years in this study. Furthermore, the discrepancies between these studies might be attributed to the different sources of patients (from surgery, radiology and gastroenterology separately). Another point of discussion in the treatment of pancreatic cysts are main-duct IPMNs and the questions if we should resect all of them, even in old and frail patients. Crippa et al. found that the impact on survival was low, even in those IPMNs with a high malignancy rate (24). Mucinous cystic neoplasms are to be resected, if they are larger than four centimeters (25). But MCNs under four centimeters also had a malignancy rate of 43% in a retrospective study by Hohn et al. (26). These recommendations are also based on retrospective surgical series, which might overestimate the rate of malignancy. Based on data of pancreatic cancer specimens, clonal evolution from the initiation of tumorigenesis until the birth of the cell giving rise to the parental clone of primary cancer takes an estimate of 11.7 years, an average of 6.8 years from then until the birth of the cell giving rise to the index primary lesion, and an average of 2.7 years from then until the patients' death

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

(27). In total, the time of tumorigenesis, here in the example of pancreatic cancer, takes 20.2 years until metastatic dissemination and death. Maybe, we can assume that in the case of pancreatic cysts, the timing is similar or even slower, illustrating the need for long-term followup data. The GERPACYST registry is therefore designed to include both patients treated by gastroenterologists, radiologist and surgeons to reduce the bias of either surveillance or resected patients. The web-based format and longitudinal study set up is supposed to facilitate inclusion and follow-up and the duration of 20 years will hopefully give the opportunity to include a large group of patients. With artificial intelligence (AI) on the rise, GERPACYST will provide a well characterized cohort to perform Al analyses with and to bring pancreatic cyst risk calculation to the next scientific level. Conclusion We established a prospective, multicenter, interdisciplinary pancreatic cyst registry to enable the uncovering of long-term pancreatic cyst biology and hope to contribute to improved patient care in the future.

perpetuity.

It is made available under a CC-BY 4.0 International license.

Trial status

10 university hospitals throughout Germany are currently participating in this study. The first patient was entered in December 2021 and the study is ongoing. It is an interdisciplinary cooperation of surgeons. radiologists and gastroenterologists. At least 5000 patients are planned to be recruited from gastroenterology and surgical departments. Baseline characteristics such as metabolic/endocrine diseases, risk factors and family history, as well as pancreatic cyst data including MPD diameter, enhanced mural nodules, calcifications and the quality of life EQ-5 questionnaire will be assessed during index visit and follow-up. Biospecimens like blood, cyst fluid and cyst cytology will be collected, if needed.

List of abbrevations

IPMN (intraductal papillary-mucinous neoplasia)

MCN (mucinous-cystic neoplasia)

SCA (serous cystic adenoma)

SPN (solid pseudopapillary neoplasia) or SPPT (Solid pseudopapillary tumors)

363

364

365

366

367 368

369

370

371

372

373

374 375

376

377

378

379 380 381

382

383

384

385

Declarations Ethics approval and consent to participate Ethical approval was given by the University of Luebeck (Az. 20-225) on July 5th, 2020. Patients are informed beforehand and give consent to participate in written form. The authors declare no financial or other competing interests. **Acknowledgements** The study is registered at https://drks.de/search/en/trial/DRKS00025927. The protocol has been reviewed and approved by the committees of each participating center. The study is endorsed by the German Pancreas Club (DPC). We thank the IT-Service Center University of Luebeck, especially Maike Wolf and Helge Illig for the establishment and maintenance of the REDCAP Database. **Author contributions** KCH was the trial sponsor and PI. The study was designed by the founding team including KCH, JM, CWM, SK, RJ, PV, MD, TK, PV, SR and UFW. UFW reviewed the statistics. All authors edited the manuscript, and read and approved the final manuscript.

References

386

- 387 1. Farrell JJ. Pancreatic Cysts and Guidelines. Dig Dis Sci. 2017;62(7):1827-39.
- 388 Ciprani D, Weniger M, Qadan M, Hank T, Horick NK, Harrison JM, et al. Risk of
- 389 malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020;20(6):1213-7.
- 390 Honselmann KC, Krauss T, Geserick S, Wellner UF, Wittel U, Hopt UT, et al. Cystic
- 391 lesions of the pancreas-is radical surgery really warranted? Langenbecks Arch Surg.
- 392 2016;401(4):449-56.
- 393 Kromrey ML, Bulow R, Hubner J, Paperlein C, Lerch MM, Ittermann T, et al.
- 394 Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of
- 395 pancreatic cysts in a population-based study. Gut. 2018;67(1):138-45.
- 396 Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al.
- 397 Revisions of international consensus Fukuoka guidelines for the management of IPMN of the 398 pancreas. Pancreatology. 2017;17(5):738-53.
- 399 Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, et al. European
- 400 experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45(9):703-401 11.
- 402 7. Vege SS, Ziring B, Jain R, Moayyedi P, Clinical Guidelines C, American
- 403 Gastroenterology A. American gastroenterological association institute guideline on the
- 404 diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology.
- 405 2015;148(4):819-22; quize12-3.
- 406 Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG Clinical Guideline: Diagnosis
- 407 and Management of Pancreatic Cysts. Am J Gastroenterol. 2018;113(4):464-79.
- 408 Muniraj T, Aslanian HR. Long-Term Follow-Up of Low-Risk Branch Duct IPMNs of
- 409 the Pancreas: Watch for Main Pancreatic Duct Dilatation, and for How Long? Clin Transl
- 410 Gastroenterol. 2018;9(10):198.
- Pergolini I, Sahora K, Ferrone CR, Morales-Oyarvide V, Wolpin BM, Mucci LA, et al. 411 10.
- 412 Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary
- 413 Mucinous Neoplasm in a Referral Center. Gastroenterology. 2017;153(5):1284-94 e1.
- 414 Han Y, Lee H, Kang JS, Kim JR, Kim HS, Lee JM, et al. Progression of Pancreatic
- 415 Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size.
- 416 Gastroenterology. 2018:154(3):576-84.
- 417 Marchegiani G, Pollini T, Burelli A, Han Y, Jung HS, Kwon W, et al. Surveillance for
- 418 Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for
- 419 Discontinuation. Gastroenterology. 2023;165(4):1016-24 e5.
- 420 Crippa S, Capurso G, Camma C, Fave GD, Castillo CF, Falconi M. Risk of pancreatic
- 421 malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review
- 422 and meta-analysis. Dig Liver Dis. 2016;48(5):473-9.
- 423 Choi SH, Park SH, Kim KW, Lee JY, Lee SS. Progression of Unresected Intraductal
- 424 Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-
- 425 analysis. Clin Gastroenterol Hepatol. 2017;15(10):1509-20 e4.
- Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 426
- 427 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ.
- 428 2013;346:e7586.
- 429 Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap 16.
- 430 consortium: Building an international community of software platform partners. J Biomed
- 431 Inform. 2019:95:103208.
- 432 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic 17.
- 433 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
- 434 translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
- 435 18. Foundation ER. EQ-5D-5L Amsterdam2024 [

- 436 19. Glicklich R, Dreyer, N., Leavy, M., eds. Registries for Evaluating Patient Outcomes: A
- User's Guide: Agency for Healthcare Research and Quality; 2014. 437
- 438 Wellner UF, Klinger C, Lehmann K, Buhr H, Neugebauer E, Keck T. The pancreatic
- 439 surgery registry (StuDoQ|Pancreas) of the German Society for General and Visceral Surgery
- 440 (DGAV) - presentation and systematic quality evaluation. Trials. 2017;18(1):163.
- 441 Handrich SJ, Hough DM, Fletcher JG, Sarr MG. The natural history of the incidentally
- 442 discovered small simple pancreatic cyst: long-term follow-up and clinical implications. AJR
- 443 Am J Roentgenol. 2005;184(1):20-3.
- 444 Kwong WT, Hunt GC, Fehmi SM, Honerkamp-Smith G, Xu R, Lawson RD, et al. Low 22.
- 445 Rates of Malignancy and Mortality in Asymptomatic Patients With Suspected Neoplastic
- 446 Pancreatic Cysts Beyond 5 Years of Surveillance. Clin Gastroenterol Hepatol. 2016;14(6):865-
- 447 71.

- 448 Marchegiani G, Pollini T, Burelli A, Han Y, Jung HS, Kwon W, et al. Surveillance for
- 449 Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for
- 450 Discontinuation. Gastroenterology. 2023.
- 451 Crippa S, Bassi C, Salvia R, Malleo G, Marchegiani G, Rebours V, et al. Low
- 452 progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk
- 453 stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut.
- 454 2017;66(3):495-506.
- 455 Crippa S, Salvia R, Warshaw AL, Dominguez I, Bassi C, Falconi M, et al. Mucinous 25.
- 456 cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.
- 457 Ann Surg. 2008;247(4):571-9.
- 458 Hohn P, Soydemir MA, Luu AM, Janot-Matuschek M, Tannapfel A, Uhl W, et al. It's
- 459 not all about the size-characteristics and risk factors for malignancy of mucinous cystic
- 460 neoplasms of the pancreas. Ann Transl Med. 2020;8(23):1572.
- 461 Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late
- 462 during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-7.

Figure 1: SPIRIT schedule of enrollment, interventions, and assessment

[STUDY PERIOD							
[Enrolment	Baseline	Follow-up				Close out	
	TIMEPOINT**	-t ₁	0	t ₁	t ₂	<i>t</i> ₃	t ₄	etc.	t _x
	ENROLMENT:								
	Eligibility screen	Х							
	Informed consent	х							
	EQ-5D-5L	х							×
medRxiv prepreprint (whi	orint doi: https://doi.org/10.101/2024.08.2 ch was new perfiliag hkipper review) is	8.24312718; this version the author/funder, who ha perpetuity. gunder a CC-BY 4.0 Intel		The copyright se to display	holder for this the preprint in	x	x	x	×
	Standard-of- care:		lational license .						
	Imaging		×	x	x	x	x	x	
	Surgery		?	?	?	?	?	?	
	ASSESSMENTS:								
	Baseline variables (Age, sex, date of first visit)		х	x	x	x	x	x	
	Comorbidities and symptoms		х	%	%	%	%	%	%
	Cyst variables (Size, number, characteristics)		x	Х	х	Х	Х	x	х

[%] Update of any new comorbidities or symptoms that have developed during follow-up ?: Surgery might occur at baseline or during follow-up